Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Executive Summary

• Zero Candida Technologies announced the design freeze of its ZC‑001 therapeutic device and the start of prototype production (50 units), with completion expected by Q1 2026.
• The milestone advances the company’s regulatory pathway and positions it for upcoming clinical validation and potential market entry in the VVC treatment space.
• Key design features—including a secure docking system, wireless encrypted data transfer, medical‑grade materials, and modular assembly—were finalized, supporting scalable manufacturing and future product extensions.

Key Details

• Design Freeze: Final specifications locked for ZC‑001 device and its SMART docking/charging case.
• Prototype Production: Initiated production of 50 prototype units; projected completion Q1 2026.
• Device Functionality: AI‑enabled therapeutic platform combining blue‑light therapy, targeted drug delivery, and wireless diagnostics for at‑home treatment of Vulvo‑Vaginal Candidiasis (VVC).
• Key Design Elements:
• Docking system for automatic alignment, charging, sterilization, and dosing accuracy.
• Wireless connectivity enabling encrypted real‑time data transmission to physicians and AI analytics.
• Light‑guide indicators for discreet status communication.
• Medical‑grade materials ensuring comfort, hygiene, and biocompatibility.
• Modular assembly facilitating scalable manufacturing and future gynecologic applications.
• Regulatory Implication: Design freeze is a critical step toward meeting regulatory requirements and advancing to clinical validation phases.
• Market Context: VVC treatment market projected > US$2 billion by 2030; the device aims to address unmet needs, especially for recurrent and drug‑resistant cases.

Notable Quotes

“Achieving design freeze and starting prototype production marks a major advancement for Zero Candida as we move closer to delivering a much needed solution for women suffering from VVC,” – Eli Ben‑Haroosh, CEO.

“Every design decision was made with patient comfort and usability in mind… defines the technical standards for how ZC‑001 will be built and tested,” – Dr. Asher Holzer, CTO.